220 related articles for article (PubMed ID: 24896629)
1. Cellular immunotherapy strategies for Ewing sarcoma.
Rossig C
Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
[TBL] [Abstract][Full Text] [Related]
2. EZH2 Inhibition in Ewing Sarcoma Upregulates G
Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
[TBL] [Abstract][Full Text] [Related]
3. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor microenvironment of Ewing sarcoma.
Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
[TBL] [Abstract][Full Text] [Related]
5. [Comparison and analysis of different dendritic cell-based immunotherapeutic strategies for Ewing sarcoma: in vitro and in vivo induction on SCID mouse models].
Zhao H; Tang S; Qu HY; Guo W; Li X; Peng CL
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 39(4):403-8. PubMed ID: 17657269
[TBL] [Abstract][Full Text] [Related]
6. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
9. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
10. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
[TBL] [Abstract][Full Text] [Related]
11. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
12. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
13. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
15. Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
Liu Z; Guo C; Das SK; Yu X; Pradhan AK; Li X; Ning Y; Chen S; Liu W; Windle JJ; Bear HD; Manjili MH; Fisher PB; Wang XY
Cancer Res; 2021 May; 81(9):2429-2441. PubMed ID: 33727225
[TBL] [Abstract][Full Text] [Related]
16. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
17. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
Altvater B; Kailayangiri S; Theimann N; Ahlmann M; Farwick N; Chen C; Pscherer S; Neumann I; Mrachatz G; Hansmeier A; Hardes J; Gosheger G; Juergens H; Rossig C
Cancer Immunol Immunother; 2014 Oct; 63(10):1047-60. PubMed ID: 24973179
[TBL] [Abstract][Full Text] [Related]
18. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.
Max D; Kühnöl CD; Burdach S; Niu L; Staege MS; Föll JL
Anticancer Res; 2014 Nov; 34(11):6431-41. PubMed ID: 25368243
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
Bhargava A; Mishra D; Banerjee S; Mishra PK
Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
